Severe COVID-19 pneumonia – Page 16 – Communicable Diseases Research

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

Observational Study

Published on 2021-02-012022-10-05
Journal: The Journal of Allergy and Clinical Immunology [Category] SARS, 임상,

Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia

중증 코로나19 폐렴을 동반한 일본 ESRD 사례 2건의 성공적인 치료

Case Reports

Published on 2021-02-012022-09-11
Journal: CEN case reports [Category] MERS, SARS, 진단, 치료제,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory distress syndrome (ARDS) Admission anti-cytokine anti-cytokine therapy ARDS Clinical course cohort study coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 pneumonia Diabetic diabetic nephropathy disease distress effective End-stage renal disease End-stage renal disease (ESRD) ESRD exhibited Hemodialysis high mortality rate ICU Immunoglobulin indicate infected with COVID-19 intensive care intensive care unit Intravenous immunoglobulin Intravenous immunoglobulin (IVIG) IVIG Japanese Maintenance hemodialysis mechanical ventilation nephropathy novel Novel coronavirus novel coronavirus disease Patient patients renal renal disease respiratory distress Respiratory distress syndrome Severe COVID-19 pneumonia syndrome Tocilizumab treated Treatment were infected with COVID-19
[DOI] 10.1007/s13730-020-00512-7 PMC 바로가기 [Article Type] Case Reports

A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient

신장이식 후 환자에서 파비피라비르와 토실리주맙으로 중증 코로나19 폐렴을 성공적으로 치료한 1예

Case Reports

Published on 2021-02-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] SARS, 진단, 치료제,

[키워드] acute diarrhea Acute kidney injury Administered Admission AKI Anti-viral treatment Azithromycin blood count caused Chain Reaction complete blood count COVID-19 COVID-19 infection darunavir diarrhea drug drug interaction Favipiravir Fever followed by high-flow nasal cannula oxygen therapy hospital Hospitalization Hydroxychloroquine IL-6 Immunosuppression infiltration initiated Interaction kidney transplant kidney transplant recipient lymphopenia MMF mycophenolate mycophenolate mofetil nasal nasal cannula nasal swab onset of fever oxygen Oxygen therapy Oxygen treatment patchy Patient PCR Pneumonia polymerase chain polymerase chain reaction Prednisolone required rising Ritonavir serum Serum IL-6 serum IL-6 level Severe COVID-19 pneumonia Stool Supportive treatment tacrolimus Tocilizumab transferred Treatment X-ray
[DOI] 10.1111/tid.13388 PMC 바로가기 [Article Type] Case Reports

A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful

LAMP법으로 검출된 혈청 SARS-CoV-2 RNA가 임상적으로 유용한 파비피라비르(아비간)로 성공적으로 치료된 코로나19 폐렴 1예

Case Reports

Published on 2021-02-012022-09-11
Journal: Journal of infection and chemotherapy : official j [Category] SARS, 치료기술, 치료제,

Microcirculation alterations in severe COVID-19 pneumonia

Observational Study

Published on 2021-02-012022-10-05
Journal: Journal of critical care [Category] 임상,

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study

Research article

Published on 2021-02-012022-10-05
Journal: International Journal of Infectious Diseases [Category] SARS, 바이오마커,

Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

중증 COVID-19 폐렴 성인 환자의 치료를 위한 Tocilizumab: 단일 센터 코호트 연구

Article

Published on 2021-02-012022-09-11
Journal: Journal of medical virology [Category] MERS, SARS, 진단, 치료제,

[키워드] 6-point ordinal scale 95% confidence interval adjusted odds ratio adverse events all-cause mortality analyzed Body body temperature C-reactive protein cardiac rate cardiac rates clinical Clinical improvement clinical status cohort study consecutive patient coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia cytokine release decrease dose dropped Evidence hospital discharge hyperinflammatory phase immunomodulation immunomodulatory therapy interferon intravenous Laboratory Lactate lactate dehydrogenase lead lymphocyte Lymphocyte count monoclonal antibody Mortality Ordinal Scale outcome oxygen oxygen saturation Patient Pneumonia Primary outcome pulse oximetry Rate receptor respiratory Safe SARS-CoV-2 secondary Secondary outcomes serum lactate severe COVID-19 Severe COVID-19 pneumonia significantly single-center single-center study TCZ temperature Tocilizumab Treatment vital sign vital signs with COVID-19
[DOI] 10.1002/jmv.26308 PMC 바로가기 [Article Type] Article

Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study

Research

Published on 2021-01-292022-10-28
Journal: Annals of Intensive Care [Category] COVID-19,

[키워드] Analysis appear Bacterial Care Cohort cohort study competing consecutive patient Control COVID-19 COVID-19 patients criteria determinant determine driven by France group higher risk historical control ICU immunomodulatory property Immunosuppression Increased independent risk factor intensive care Invasive mechanical ventilation investigated laboratory-confirmed SARS-CoV-2 infection mechanical ventilation mechanically ventilated patient multicentre occurred outcome Patient Pneumonia remained Result retrospective retrospective cohort study risk Septic shock Seven severe COVID-19 severe COVID-19 patient Severe COVID-19 pneumonia severe SARS-CoV-2 susceptibility the SARS-CoV-2 three groups time Ventilator-acquired pneumonia Viral pneumonia
[DOI] 10.1186/s13613-021-00812-w PMC 바로가기 [Article Type] Research

ACE Gene I/D Polymorphism and Acute Pulmonary Embolism in COVID19 Pneumonia: A Potential Predisposing Role

Medicine

Published on 2021-01-212022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] absence ACE ACE gene ACE2 activity Angiotensin II assessment case-control study conducted counterbalance COVID-19 COVID-19 disease COVID-19 patient COVID19 COVID19 pneumonia Embolism expressed genetic risk factor genetic susceptibility heterozygote high risk homozygous I/D I/D polymorphism Infection investigated involved Italy MOST Naple Occurrence Patient patients with SARS-CoV-2 pilot study Pneumonia polymorphism Population Potential Prevalence pulmonary pulmonary angiography Pulmonary embolism retrospective role Severe COVID-19 pneumonia significantly higher significantly lower single-center statistically significant difference subject thromboembolic complication Thromboembolism unit
[DOI] 10.3389/fmed.2020.631148 PMC 바로가기 [Article Type] Medicine

Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

입원 환자의 COVID-19 치료에 대한 회복기 혈장 대 치료 표준 평가: 2상 무작위, 공개, 대조, 다기관 시험을 위한 연구 프로토콜

Study Protocol

Published on 2021-01-202022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 7-point ordinal scale Acute respiratory infection acute respiratory infections Administered Adult patients Analysis antibodies assigned cause caused center clinical trial Complete conducted contribute Controlled trial convalescent plasma Convalescent plasma (CP) COVID-19 COVID-19 infection COVID-19 pneumonia effective Efficacy Efficacy and safety enrolled etiology evaluate expected futility Hospitalized hospitalized patients immune response Immunotherapy include infected patient infected patients Interim Interim analyses intravenously invasive mechanical ventilation morbidity and mortality multicenter Multicenter trial Neutralizing antibodies Non-invasive Novel coronavirus Open-label option Ordinal Scale Patient patients hospitalized pharmacological primary endpoint proportion protocol Randomized Randomly receive respiratory Respiratory disease Sample size SARI SARS-CoV-2 Severe COVID-19 Infection Severe COVID-19 pneumonia severity Standard of care stratified Study protocol supplementary material the WHO therapeutic agent therapeutic agents Therapeutics Treatment treatment arm Trial registration Vaccine variety Viral viral disease with COVID-19
[DOI] 10.1186/s13063-020-05011-9 PMC 바로가기 [Article Type] Study Protocol